MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the “Class Period”), of the important October 9, 2020 lead plaintiff deadline in the securities class action.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Reminds MEI Pharma, Inc. Investors of the Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – MEIP

NEW YORK, Aug. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of the Important Deadline in Securities Class Action - MEIP

New York, New York--(Newsfile Corp. - August 19, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc.

MEIP INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

NEW YORK, Aug. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc.

ROSEN, A GLOBALLY RECOGNIZED FIRM, Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - MEIP

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired MEI Pharma securities in the U.S.

MEIP INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.

Shareholder Alert: Robbins LLP Announces MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

LOS ANGELES--(BUSINESS WIRE)---- $MEIP #MEIP--SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 11, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #MEIP--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Intel Corporation (NASDAQ: MEIP) securities between August 2, 2017 and July 1, 2020 (the “Class Period”).

MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $MEIP #MEIP--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the “Class Period”).

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc. – MEIP

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.

Pomerantz Law Firm Announces the Filing of a Class Action against MEI Pharma, Inc.  and Certain Officers - MEIP

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc.

MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020

MEIP just disclosed its licensee will discontinue Pracinostat development sending shares down below $3. With ~$200MM cash and $0 debt, MEIP's fully diluted enterprise valuation totals ~$130MM (rounded) at $2.95/share.

MEI Pharma Is Oversold Vs. The Value Of A Recent Executed Agreement And Peer Company Valuation

NEW YORK, July 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP). Investors who purchased MEI Pharma securities are encouraged to...

MEIP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MEI Pharma, Inc. and Encourages Investors to Contact the Firm

NEW YORK, July 2, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ: MEIP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc. - MEIP

A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.

Why MEI Pharma Is Tanking 15.3% Today

AbbVie

Ollie's Bargain Outlet Hlds

Vistra Energy

Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

Go Defensive to Beat Market Turbulence With These 4 Stocks

Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?

MEI Pharma (NASDAQ: MEIP) shares are trading higher on Friday. SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and a price target of $16 per share.

Why MEI Pharma's Stock Is Trading Higher Today

Avenue Therapeutics

Concert Pharma

Minerva Neurosciences

Ocular Therapeutix

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

ADTRAN Holdings Inc

Etsy

Inovio Pharmaceuticals

Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.

Tap the Solid Momentum in These 5 Solid High-Beta Stocks

MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

News for MEI Pharma Stock (MEIP)